Head to Head Analysis: Galmed Pharmaceuticals (NASDAQ:GLMD) and Merck KGaA (OTCMKTS:MKGAF) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play (NASDAQ:MDGL) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends. Volatility and Risk Connect Biopharma has a […]
/PRNewswire/ The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S..
Equities analysts predict that Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Rating) will announce earnings of ($0.34) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Galmed Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.26). Galmed Pharmaceuticals reported earnings per share of ($0.38) […]